JAK2V617F 돌연변이를 보인 비정형만성골수성백혈병 1예
A Case of Atypical Chronic Myeloid Leukemia with the JAK2V617F Mutation
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Atypical chronic myeloid leukemia (aCML) is a rare leukemic disorder that shows myelodysplastic and myeloproliferative features simultaneously. The Janus kinase 2 gene V617F mutation (JAK2V617F) in aCML has been the source of much controversy. Some JAK2V617F positive cases have been reported but others observed no JAK2V617F mutation in aCML as defined by WHO classification. Recently, we experienced a case of aCML with JAK2V617F mutation with typical myelodysplastic/myeloproliferative features in peripheral blood and bone marrow aspirates. The karyotype was normal and no BCR/ABL1, PDGFRA or PDGFRB gene rearrangement was noted with FISH analysis. JAK2V617F mutation of the case was identified with amplification refractory mutation system PCR and direct sequencing. We also studied JAK2V617F mutation status in 3 additional cases of previously diagnosed aCML in our institution, but no mutation was identified.Atypical chronic myeloid leukemia (aCML) is a rare leukemic disorder that shows myelodysplastic and myeloproliferative features simultaneously. The Janus kinase 2 gene V617F mutation (JAK2V617F) in aCML has been the source of much controversy. Some JAK2V617F positive cases have been reported but others observed no JAK2V617F mutation in aCML as defined by WHO classification. Recently, we experienced a case of aCML with JAK2V617F mutation with typical myelodysplastic/myeloproliferative features in peripheral blood and bone marrow aspirates. The karyotype was normal and no BCR/ABL1, PDGFRA or PDGFRB gene rearrangement was noted with FISH analysis. JAK2V617F mutation of the case was identified with amplification refractory mutation system PCR and direct sequencing. We also studied JAK2V617F mutation status in 3 additional cases of previously diagnosed aCML in our institution, but no mutation was identified.
Abstract
Atypical chronic myeloid leukemia (aCML) is a rare leukemic disorder that shows myelodysplastic and myeloproliferative features simultaneously. The Janus kinase 2 gene V617F mutation (JAK2V617F) in aCML has been the source of much controversy. Some JAK2V617F positive cases have been reported but others observed no JAK2V617F mutation in aCML as defined by WHO classification. Recently, we experienced a case of aCML with JAK2V617F mutation with typical myelodysplastic/myeloproliferative features in peripheral blood and bone marrow aspirates. The karyotype was normal and no BCR/ABL1, PDGFRA or PDGFRB gene rearrangement was noted with FISH analysis. JAK2V617F mutation of the case was identified with amplification refractory mutation system PCR and direct sequencing. We also studied JAK2V617F mutation status in 3 additional cases of previously diagnosed aCML in our institution, but no mutation was identified.Atypical chronic myeloid leukemia (aCML) is a rare leukemic disorder that shows myelodysplastic and myeloproliferative features simultaneously. The Janus kinase 2 gene V617F mutation (JAK2V617F) in aCML has been the source of much controversy. Some JAK2V617F positive cases have been reported but others observed no JAK2V617F mutation in aCML as defined by WHO classification. Recently, we experienced a case of aCML with JAK2V617F mutation with typical myelodysplastic/myeloproliferative features in peripheral blood and bone marrow aspirates. The karyotype was normal and no BCR/ABL1, PDGFRA or PDGFRB gene rearrangement was noted with FISH analysis. JAK2V617F mutation of the case was identified with amplification refractory mutation system PCR and direct sequencing. We also studied JAK2V617F mutation status in 3 additional cases of previously diagnosed aCML in our institution, but no mutation was identified.
참고문헌 (14)
- Bennett JM, "The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia", Br J Haematol, 87, pp.746~754 (1994), Proposals by the French-American-British Cooperative Leukaemia Group
- Swerdlow SH, "WHO classification of tumours of haematopoietic and lymphoid tissues", pp.80~81 (2008), IARC Press
- Hall J, "Diagnosing myelodysplastic", myeloproliferative neoplasms: laboratory testing strategies to exclude other disorders, 2010, pp.32, 559~571
- Fend F, "Atypical chronic myeloid leukemia as defined in the WHO classification is a JAK2 V617F negative neoplasm", Leuk Res, 32, pp.1931~1935 (2008)
- Campiotti L, "JAK2 mutation and atypical chronic myeloid leukemia", Leuk Res, 33, pp.166~167 (2009)
- 유수진, "비전형 만성골수성백혈병 4예", Annals of Laboratory Medicine, 22(2), pp.75~79 (2002), 대한진단검사의학회
- Hyun Woo Kim, "A Case of Leukemic Pleural Infiltration in Atypical Chronic Myeloid Leukemia", Journal of Korean Medical Science, 21(5), pp.936~939 (2006), 대한의학회
- 조희순, "비전형 만성골수성백혈병의 골수성 아세포기 1례", 대한혈액학회지, 38(3), pp.9~204 (2003), 대한혈액학회
- Jones AV, "Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders", Blood, 106, pp.2162~2168 (2005)
- Levine RL, "The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia", Blood, 106, pp.3377~3379 (2005)
- Jelinek J, "JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia", Blood, 106, pp.3370~3373 (2005)
- Boyle EB, "Accuracy of DNA amplification from archival hematological slides for use in genetic biomarker studies", Cancer Epidemiol Biomarkers Prev, 7, pp.1127~1131 (1998)
- Ernst T, "Transcription factor mutations in myelodysplastic", myeloproliferative neoplasms, 2010, pp.95, 1473~1480
- Pérez B, "Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia", Br J Haematol, 151, pp.460~468 (2010)